Navigation Links
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Date:5/30/2008

of given genes and the clinical response induced by the MAGE-A3 ASCI in metastatic melanoma(2).

In addition, GSK presented data on the genetic profiling of patients with NSCLC. In a retrospective analysis, a predictive gene signature similar to that observed in melanoma was associated with a lower rate of disease recurrence in the MAGE-A3 treated group(3).

"These phase II data mark another significant milestone for the development of the MAGE-A3 ASCI as a potential novel cancer therapy. Validation of a predictive gene signature, combined with selection of patients who express cancer antigens of interest, may allow GSK to improve predictions of a patient's clinical response to treatment with cancer immunotherapeutics," said Johan Vansteenkiste, Professor of Internal Medicine, Faculty of Medicine, Catholic University of Leuven, Belgium. "They also provide further positive proof-of-concept Phase II data which highlight the importance of the ongoing MAGRIT Phase III trial in Non-Small Cell Lung Cancer."

Phase II Melanoma Data: abstract # 9065(1)

A randomized, open-label Phase II study designed to evaluate MAGE-A3 recombinant protein combined with two different Adjuvant Systems was conducted. A total of 72 patients with measurable metastatic MAGE-A3-positive cutaneous melanoma (unresectable or in transit stage III or stage IV M1a) were randomized to receive immunization with MAGE-A3 protein combined with either AS15 or AS02B as first-line metastatic treatment. Patients were to receive a maximum of 24 immunizations over four years. Clinical activity is assessed by the RECIST criteria, the international standards for evaluation of solid tumors. Complete response (CR) and partial response (PR) i.e, disappearance or significant reduction of tumor, were reported in four patients in the AS15 group (3 CR and 1 PR) with two of these ongoing for more than two years; in the AS02B arm, one patient showed a partial response which lasted for 6 months.1 The
'/>"/>

SOURCE GlaxoSmithKline (GSK)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Genmab Announces Updates on Phase III Cancer Studies
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
6. Prostate Cancer Treatment Offers Results Without Side Effects
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
9. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... May 11, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... the 2011 UBS Global Specialty Pharmaceuticals Conference in London ... The presentation will be simultaneously webcast and ...
... Inc. (OTC Bulletin Board: NEPH ), a ... therapeutic applications, infection control, and water purification, today announced ... from the Therapeutic Products Directorate of Health Canada, the ... Ultrafilters (DSU) in Canada to filter out biological contaminants ...
Cached Medicine Technology:Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 2Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 3Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 4
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... , and launched a bamboo flooring promotion with great ... Jan. 30, 2015. , According to the CEO of ... flooring available today; it has a highly distinctive grain ... Strand woven bamboo is made by a unique manufacturing ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses ... new designs in this collection, and all of them ... AngelWeddingDress.com promises to provide the most fashionable designs ... many fashion trends come and go. If ladies have ... AngelWeddingDress.com is ready to assist. , “These new ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading ... same time helping people get their health back. Mission ... to serving those persons in Muskegon County who are unable ... quality of life. Dr. Michael Rykse wanted to do a ... community and he knew he found that when he heard ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Theme ... announced a new intro plugin for Final Cut Pro ... pictures, videos, logos, and more with absolute ease.” Said ... our users the tools needed to easily animate their ... Final Cut Pro X users to animate pictures, videos, ...
(Date:12/20/2014)... is a professional company offering many kinds of ... its new engineered bamboo flooring collection, and announced a ... BambooIndustry.com’s customers come from many countries in the world: ... CEO of the company, the global bamboo flooring market ... years, and the demand for eco-friendly bamboo flooring products ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2
... and drinking plenty of water are the best ways to ... their growth among children, say paediatricians.// ,Kidney stones ... and can cause urinary tract infections. Signs and symptoms of ... in the sides, frequent and painful urination, blood in the ...
... Administering Testosterones can slow down the progression of Alzheimer's ... Testosterone, the primary male sex hormone, is one// in ... androgens. , The findings, published in the ... new insight into the relationship between testosterone loss and ...
... about 'DNA-diets', advertised extensively on the internet, making tall claims ... ,A study, spearheaded by researchers at the Economic and ... the University of Exeter, is the first study of its ... DNA diets are also called 'nutrigenomic' diets that are customized ...
... children in three months in Uttar Pradesh, leaving health authorities ... encephalitis killed at least 400 children in eastern Uttar Pradesh ... the region claiming children as victims. ,'The killer ... a loss as to how we should tackle it,' said ...
... removed from her leg in November, the White House has said.// ... biopsy of a small sore on the shin of her right ... said Monday evening. ,Doctors identified it as a squamous ... ,"Because of Mrs. Bush's early detection and treatment the area ...
... The South Nassau Communities Hospital here has appointed a noted ... is recognised as a leading head and neck surgeon in ... oncology. ,"This is truly a career highlight and I ... medical community in this capacity," Datta said. ...
Cached Medicine News:Health News:Drinking Plenty of Water may Prevent Kidney Stones 2Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2
... The ESR-10 Manual Rack is ... for determining the erythrocyte sedimentation rate ... minutes using 1.2ml Streck ESR-Vacuum Tubes. ... 10 tubes simultaneously. The ESR-10 Manual ...
... use as a sheath fluid when performing ... of Cytometry Concentrate dilutes to 3L of ... Cubitainers, Streck Cytometry Concentrate reduces heavy lifting, ... compromising performance. Streck Cytometry Concentrate has a ...
... is a stabilized preparation of ... be used as a complete ... positive cells. It is compatible ... gating strategies. CD-Chex CD34 has ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Medicine Products: